Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
LadRx Corporation Announces OTCQB Ticker Change to LADX Business Wire - Wed Oct 5, 2022

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing...

CYTR : 0.0920 (unch)
LADX : 0.7372 (-18.09%)
CytRx Corporation Relaunches as LadRx Corporation Business Wire - Fri Sep 23, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching...

CYTR : 0.0920 (unch)
European Patent Office Awards CytRx Key Patent Business Wire - Wed Sep 7, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded...

CYTR : 0.0920 (unch)
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors Business Wire - Tue Aug 9, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne...

CYTR : 0.0920 (unch)
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock Business Wire - Thu May 19, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board...

CYTR : 0.0920 (unch)
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc. Business Wire - Tue May 17, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic...

CYTR : 0.0920 (unch)
CytRx Partners with Oncology Development Expert to Advance LADR Platform Business Wire - Wed Apr 20, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered...

CYTR : 0.0920 (unch)
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress Business Wire - Mon Mar 21, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to...

CYTR : 0.0920 (unch)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C Business Wire - Thu Feb 24, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C Business Wire - Mon Feb 14, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)

Barchart Exclusives

Stocks Slip Before the Open on Nvidia’s Disappointing Forecast and Ukraine Jitters, U.S. Economic Data on Tap Barchart - 32 minutes ago
December S&P 500 E-Mini futures (ESZ24) are down -0.31%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.43% this morning as a disappointing revenue forecast from Nvidia and concerns about escalating Russia-Ukraine tensions dampened sentiment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot